Quarter Comparison
Revenue
Net Margin
EPS (Diluted)
Income Statement
Cash Flow Statement
Balance Sheet
Earnings Release
EX-99.1 2 coya-ex99_1.htm EX-99.1 EX-99.1 Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc.
EX-99.1 2 coya-ex99_1.htm EX-99.1 EX-99.1 Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update HOUSTON, TX., August 11, 2026 (BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended June 30, 2026 and provides a corporate update. “During the second quarter, we made notable progress advancing our lead program, COYA 302,” said Arun Swaminathan, Ph.D., Chief Executive Officer of Coya. “Enrollment in the ALSTARS Phase 2 ALS trial is proceeding as planned, and we remain on track to complete enrollment this year and report topline data in the first quarter of 2027. At the same time, we plan to initiate a Phase 2 study of COYA...
Source
Exhibit EX-99.1
0001193125-26-343473
Filed August 11, 2026 at 12:03 PM UTC. The figures above are from the audited statements, not from this release.